Navigation Links
Innovations in Injectables: Current and emerging technologies to improve drug delivery

NEW YORK, Nov. 8, 2010 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Innovations in Injectables: Current and emerging technologies to improve drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides. Although a relatively underdeveloped market at present the injectable drug delivery has a substantial pipeline, and with significant strides in development of nanotechnology and DNA drug delivery over the past 5 years, injectable drug delivery is set to be an important component of the future pharmaceuitical landscape.

This report evaluates the current and evolving technologies used for injectable drug delivery, the key therapuetic areas, the barriers and driving forces for this market, the competitive landscape is analysed according the technology type, and key pipeline companies and products are examined. Leading companies in the injectable drug delivery market are also profiled.

Key Features of this report• Overview of injectable drug delivery technologies and their mechanisms.

• Profile of key therapeutic areas for injectable drug delivery including, acromegaly, diabetes, hepatitis C, HIV, oncology, pain, schizophrenia and substance abuse.

• Analysis of key therapeutic areas will include incidence rates, current injectable treatments and future directions for injectable drug delivery in this area.

• Market drivers for injectable drug delivery will be examined including patient adherence and the reduction of toxicity, as well as how advances in nanotechnology and genomics are driving the market.

• The threat from alternative delivery methods will also be examined as well as current regulatory issues.

Scope of this report• Understand current market dynamics and drivers for injectable drug delivery.

• Understand the injectable drug delivery market in terms of segment sizes as well as market shares.

• Understand the key technologies used for injectable drug delivery and their mechanisms.

• Evaluate major market participants, their technologies, pipeline and weaknesses and strengths.

• Develop an understand of the developmental pipeline for injectable drug delivery and key innovations driving the future direction of the market.

Key Market Issues• Injectable drug delivery has a significant potential to drive the future market, however, at present only a few key products have enjoyed significant market success.

• Nanotechnology and DNA drug delivery are set to shape future markets significantly, both have a very strong pipeline, but DNA delivery has yet to have any proven market success.

• Therapy areas where adherence is a significant problem area present a major area of opportunity for injectable delivery. Current key market successes such as Risperdal Consta demonstrate the role that injectable delivery has to play in overcoming adherence problems, and future potential in areas such as mental health, diabetes and HIV are set to ensure the continued success of injectable delivery.

Key findings from this report• The injectable drug delivery market holds great potential but is still in its infancy. Successes so far are dominated by just a few products.

• The injectable delivery pipeline is very strong and disproportionate at present to the current market, suggesting it may have a much more significant influence on the future market with the increased use of proteins and peptides.

• DNA technology is yet to prove successful, despite significant investment and research there has been only 1 successful marketed product, which has not achieved great market success.

• Nanotechnology holds the greatest potential for success in the near future. Current products enjoy some increasing success and there is a strong pipeline with products in high revenue therapy areas.

• Although sustained release products will continue to be used, there is little development in this field with a greater move towards nanotechnology and DNA drug delivery.

Key questions answered• What are the key technologies used to enable drug delivery using injections?

• What are the mechanisms of key technologies?

• What are the key therapy areas for injectable drug delivery? What is their incidence?

• What products are used at present for key therapy areas and how will injectable delivery shape the future treatment of these therapy areas?

• What is the size of the current injectable delivery market and what is the share of the key products and market participants?

Companies mentionedAlkermes, Bioject, Debiopharm, Elan Drug Technologies, Enzon, Ferring International, Nektar, QLT

Table of ContentsInnovations in injectables

Executive Summary 10

Introduction 10

Key therapeutic areas for injectables 11

Market drivers and barriers 13

Competitive landscape 14

Company profiles of key players 15

Conclusions 16

Chapter 1 Introduction 20

Summary 20

Introduction 21

Types of injectable drug delivery 23

Controlled release 23

Mechanisms of controlled release 24

Drivers and restraints for controlled release formulations 25

Needle free delivery 26

Mechanisms of needle free delivery 27

Drivers and restraints for needle free technologies 29

Nanotechnology and microspheres 30

Mechanisms of nanotechnology drug delivery 31

Drivers and restraints – nanotechnology 35

Gene based drug systems 35

Electrical techniques 37

Vector assisted delivery 37

Drivers and restraints – gene based drug systems 38

Chapter 2 Key areas for injectable drug delivery 42

Summary 42

Introduction 44

Acromegaly 44

Background to therapeutic area 44

Current treatments 45

Looking forward 46

Diabetes 46

Background to therapeutic area 46

Type 1 diabetes 47

Type 2 diabetes 47

Current treatments 48

Looking forward 49

Hepatitis C 50

Background to therapeutic area 50

Current treatments 51

Looking forward 51

HIV 52

Background to therapeutic area 52

Current treatments 53

Looking forward 53

Oncology 54

Background to therapeutic area 54

Current treatments 55

Looking forward 56

Pain 57

Schizophrenia and substance abuse 58

Background to therapeutic areas 58

Current treatments 59

Schizophrenia 59

Substance abuse 59

Looking forward 60

Chapter 3 Market drivers and resistors 62

Summary 62

Key drivers 63

Improving patient compliance 63

Reducing toxicity 65

Advances in nanotechnology 66

Advances in genomics 69

Resistors 71

The threat from alternative delivery methods 71

Oral delivery of proteins and peptides 71

Pulmonary delivery of proteins and peptides 72

Transdermal delivery of proteins and peptides 73

Conclusion 75

Regulatory issues 75

Nanotechnology regulation 75

Gene therapy regulation 76

Regulations impacting needle free injections 77

Chapter 4 Competitive landscape 80

Summary 80

Overall injectables market 81

Sustained release 81

Marketed products and market share 81

Emerging technologies 84

Nanotechnology 88

Marketed products and market share 88

Emerging technologies 91

Other novel injectable formulations 96

Marketed products and market share 96

Emerging technologies 96

Chapter 5 Company profiles of key players 104

Summary 104

Introduction 105

Alkermes 106

Technology platforms 106

Product pipeline 107

SWOT analysis 109

Bioject 109

Technology platforms 110

Product pipeline 110

SWOT analysis 112

Debiopharm group 113

Technology platforms 113

Product pipeline 114

SWOT analysis 117

Elan 117

Technology platforms 118

Product pipeline 119

SWOT analysis 121

Enzon pharmaceuticals 121

Technology platforms 122

Pipeline 123

SWOT analysis 125

Ferring 125

Technology platforms 126

SWOT analysis 127

Nektar therapeutics 127

Technology platforms 128

Pipeline 129

SWOT analysis of Nektar 134

QLT 134

Technology platforms 135

Pipeline 135

SWOT analysis for QLT 136

Chapter 6 Conclusions 138

Summary 138

Conclusions 138

Index 141

List of FiguresFigure 1.1: Liquid jet injection technology vs. needled injection 28

Figure 1.2: Glide SDI solid dosing needle free delivery 28

Figure 1.3: Liposomal drug delivery 33

Figure 2.4: Distribution of Global Cancer Burden by WHO Region (2008) 55

Figure 4.5: Sustained release injectable market share analysis of leading products worldwide 2008 82

Figure 4.6: Sustained release injectable market share analysis of leading drug delivery companies 2008 84

Figure 4.7: Nanotechnology injectable market share analysis of leading products worldwide 2008 89

Figure 4.8: Nanotechnology injectable market share analysis of leading drug delivery companies 2008 90

Figure 5.9: Medisorb microsphere technology 107

Figure 5.10: Alkermes product pipeline, Dec, 2009 108

Figure 5.11: SWOT analysis of Alkermes 109

Figure 5.12: Bioject pipeline 111

Figure 5.13: SWOT analysis of Bioject 112

Figure 5.14: Debiopharma pipeline 116

Figure 5.15: SWOT analysis of Debiopharm 117

Figure 5.16: Elan's product pipeline 120

Figure 5.17: SWOT analysis of Elan 121

Figure 5.18: Enzon's product pipeline 123

Figure 5.19: SWOT analysis of Enzon 125

Figure 5.20: SWOT analysis of Ferring 127

Figure 5.21: Nektar's product profile 133

Figure 5.22: SWOT analysis of Nektar 134

Figure 5.23: SWOT analysis of QLT 136

List of TablesTable 1.1: Drivers and barriers for the use of injections in delivering drugs 22

Table 1.2: The role of innovative drug delivery technologies 23

Table 1.3: Types of microspheres 34

Table 1.4: DNA delivery methods 37

Table 2.5: Acromegaly – key injectable therapies 46

Table 2.6: Estimated numbers of people with diabetes by region for 2000 and 2030 and summary of population changes 48

Table 2.7: Key injectable therapies for Diabetes 50

Table 2.8: Estimated incidence of hepatitis C by WHO region 51

Table 2.9: Hepatitis C key injectable therapies 51

Table 2.10: Regional HIV Statistics 2001 and 2007 52

Table 3.11: Notable drug delivery companies / platforms - nanotechnology 68

Table 3.12: Notable drug delivery companies / platforms - genomics 70

Table 4.13: Worldwide injectables market 81

Table 4.14: Sustained release injectable market share & CAGR analysis of leading products worldwide 2008 82

Table 4.15: Sustained release injectable drug delivery companies market share analysis worldwide

2008 83

Table 4.16: Patent expiry leading sustained release compounds (still in patent) 84

Table 4.17: Selected emerging technologies in sustained release 86

Table 4.18: Nanotechnology injectable market share & CAGR analysis of leading products worldwide 2008 89

Table 4.19: Nanotechnology injectable drug delivery companies market share analysis worldwide 2008 90

Table 4.20: Patent expiries of leading nanotechnology compounds (still in patent) 90

Table 4.21: Selected emerging technologies in nanotechnology 91

Table 4.22: Selected emerging technologies in nanotechnology 97

Table 5.23: Alkermes in brief 106

Table 5.24: Bioject in brief 109

Table 5.25: Debiopharm group in brief 113

Table 5.26: Elan in brief 117

Table 5.27: Enzon in brief 121

Table 5.28: Ferring in brief 125

Table 5.29: Nektar in brief 127

Table 5.30: QLT in brief 134

To order this report:Drug Delivery Technology Industry: Innovations in Injectables: Current and emerging technologies to improve drug delivery

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
2. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
3. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
4. Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit
5. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
6. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
7. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
8. TCP Innovations Opens First US Office
9. Cleveland Clinic Unveils Top 10 Medical Innovations for 2010
10. Sonitus Medical Technology Ranks #1 on Cleveland Clinics Top 10 Medical Innovations for 2010
11. Young Innovations, Inc. Provides Third Quarter Conference Call Details
Post Your Comments:
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more ... to dairy proteins, providing direct cost savings as well as more stable pricing ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop ... Mirroring360 Pro . This new addition to the Mirroring360 product family combines device ... business. , Mirroring360 Pro enables educators, business professionals and individuals to stream or ...
(Date:4/25/2017)... ... 25, 2017 , ... As President Trump challenges the status ... his administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, ... to make it through Congress. His discussion will focus on the current state ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... 25, 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis ... –can’t help but be heartened by the industry’s current surge. But another thing that ... “skunk smell.” At last they can simply, safely and effectively end their aroma ...
Breaking Medicine News(10 mins):